Update, November 2, 2026
UnitedHealth Group (UNH) has slipped 1.6% over the past five sessions, underperforming the S&P 500's 0.6% decline and the healthcare sector ETF XLV's 3.1% gain, as of November 2, 2026. The stock is down 4.9% from its October 22 peak of 424.98, pressured by news that insurers, including UNH, are cutting Medicare Advantage plans for 2027 due to lower federal reimbursement rates and rising medical costs (Yahoo! Finance). Additionally, Mark Cuban's comments about AI exposing overcharging by major insurers have added bearish sentiment (Yahoo! Finance).
Despite the pullback, the picture holds. The stock remains above its 40-week average and the 50-day SMA at 390.47, with the daily trend still aligned with the weekly uptrend. The key level to watch is the swing zone at 405.64, which now acts as resistance after the stock closed below it on October 22; a daily close above that level on above-average volume would signal an upside breakout, with targets at 415.18 and 436.35. Support sits at 400.0 (round) and 398.19 (swing zone), with a weekly close below 390.47 what would change the picture. The 5-day underperformance versus XLV (-4.7%) is a concern, but the 50-day relative strength versus SPY (+4.4%) still favors the bullish stance, now with medium conviction.
UnitedHealth Group (UNH) has jumped to about $422 after a third-quarter earnings beat and a raised full-year outlook, gaining 11.7% in five days while the S&P 500 fell. The balance of evidence leans positive for the next two to six weeks, with high conviction, because the daily trend, the weekly trend and relative strength all agree. The catch is price: the stock is stretched, and the math from a breakout reaches only 0.9 to 1.
Why it matters
The quarter was a clean beat. Benzinga reports adjusted earnings of $4.69 a share against $4.12 expected, and a medical loss ratio of 88.4% against 89.9% expected. That ratio is the share of premiums paid out as care, so a lower figure means cost pressure is easing. Management then raised its full-year adjusted EPS outlook to at least $20.50, according to CNBC. It also reiterated its 13% to 16% long-term growth target, as The Motley Fool summarizes, citing operational reforms now taking effect.
The first reaction was modest: shares rose 3.95% to $411.23 on Thursday. The bigger move came later. UNH is up another 3.7% today, 11.7% over five days and 12.0% over a month, and none of the news explains today's jump specifically. The sector helped: XLV gained 5.9% over five days and 2.3% today, while SPY lost 1.1% over five days. That makes the market a headwind, the sector responsible for roughly half the move, and the stock itself about 5.8 points ahead of its sector. PR Newswire notes that health care led the week as technology sold off after a hotter inflation report. UNH has been the strongest part of that rotation.
The debate about UNH is lopsided. The positive case is that earnings are recovering fast: a Seeking Alpha author rates the stock a Buy after operating earnings grew more than 50% on essentially flat revenue. Morgan Stanley's Erin Wright reiterated a $529 price target, the top of the analyst range. The cautious side has no UNH-specific article in this batch. The same Seeking Alpha facts show profit growth coming from margins rather than sales. The broader worries are about the market: NASDAQ lists higher rates, elevated valuations, the war in Iran and the midterm elections. A side story, nine companies including UNH objecting to listing on a tokenized-share venue, Decrypt reports without any stated reason, and it has no visible bearing on the price.
On valuation, 25 analysts rate the stock a buy on average, with a mean target of $477.84, which puts the price 11.7% below it. Targets run from $380 to $529, so the lowest is now below the market price. The stock has moved toward the consensus quickly, and a good part of the good news is already in the price.
What the evidence says
The long-term thesis is intact. Price is above its 40-week average, the 50-day average ($387.56) sits well above the 200-day ($359.91), and the stock is up 30.5% over six months and 27.8% year to date, against 12.9% for SPY and 16.1% for XLV. It trades 62.9% above its 52-week low of $259.02 and 3.3% below its high of $436.35. That is an advanced phase of a recovery: the repair has been made, and the stock is now near the top of its year's range.
For the next two to six weeks the balance of evidence leans positive, and conviction is high, at three of four points. The daily trend runs with the weekly uptrend. UNH leads the S&P 500 by 8.8% over 50 days and XLV by 3.3%. Earnings gave the move a fundamental reason, and the rally has come while the broader market slipped.
The strongest case against is stretch. RSI is 81.4, deeply overbought, and today's volume is running 46.1% below its 20-day average, though the session is not over. Past instances of RSI crossing above 70 were followed by a higher price a month later 58.7% of the time, against 61.8% for the stock's typical month. The median one-month move was only 0.92% across 583 cases. This does not tip the balance, since the trend and relative strength still point up. It does show that the next month's gain may be small, and it is why conviction is not higher.
Levels that matter
The structure holds above $415.18, a swing zone where price has turned before. A move under it would be the first crack. The trend ends below $405.64, the next swing zone. Below that sit $400, then $398.19, then the 50-day average at $387.56.
The breakout level is a daily close above $425 on volume above its 20-day average, a condition today's volume does not yet meet. From $425 the first target is the 52-week high of $436.35, against a stop at $411.86, which is $415.18 minus a quarter of the $13.30 average daily range. That gives 0.9 to 1, well short of the 3 to 1 that makes a breakout worth the risk. Reaching 3 to 1 would take a target far beyond the 52-week high, with $450 the next marked resistance, or a much tighter stop.
What would change the picture
A weekly close below $405.64 would change the picture, because it would end the structure of higher swing lows. The non-price fact that would do it is a reversal in medical costs: a medical loss ratio climbing back toward the 89.9% the market had expected, or guidance falling below the $20.50 floor. Either would undercut the recovery story the rally rests on.
What to watch
- Earnings, January 12, 2027: the medical loss ratio against Q3's 88.4%, and whether the outlook of at least $20.50 holds.
- Sector: XLV and managed-care peers such as CVS, Humana and Cigna often move the stock before its own news. Inflation and rate headlines are driving the rotation into health care.
- Valuation: $422 sits 11.7% below the $477.84 mean target, inside a $380 to $529 range, so the consensus implies room but no longer a bargain.